Hoth Therapeutics (NASDAQ:HOTH) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Hoth Therapeutics (NASDAQ:HOTH) to a sell rating in a report issued on Saturday morning.

A number of other equities research analysts have also recently issued reports on HOTH. Weiss Ratings restated a “sell (e+)” rating on shares of Hoth Therapeutics in a report on Monday, December 22nd. D. Boral Capital reiterated a “buy” rating and issued a $5.00 price objective on shares of Hoth Therapeutics in a research note on Wednesday, March 4th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Hoth Therapeutics currently has an average rating of “Hold” and a consensus price target of $5.00.

Hoth Therapeutics Trading Down 0.3%

Shares of Hoth Therapeutics stock opened at $0.99 on Friday. The firm has a fifty day simple moving average of $1.00 and a 200-day simple moving average of $1.23. The stock has a market capitalization of $15.36 million, a price-to-earnings ratio of -0.93 and a beta of 0.50. Hoth Therapeutics has a 1-year low of $0.66 and a 1-year high of $2.12.

Institutional Investors Weigh In On Hoth Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of HOTH. DRW Securities LLC bought a new stake in Hoth Therapeutics in the fourth quarter valued at about $257,000. Geode Capital Management LLC raised its stake in shares of Hoth Therapeutics by 18.0% in the fourth quarter. Geode Capital Management LLC now owns 181,112 shares of the company’s stock valued at $179,000 after acquiring an additional 27,577 shares during the last quarter. Citadel Advisors LLC acquired a new position in shares of Hoth Therapeutics in the 3rd quarter worth approximately $232,000. Virtu Financial LLC acquired a new position in shares of Hoth Therapeutics in the 3rd quarter worth approximately $184,000. Finally, Kestra Private Wealth Services LLC bought a new stake in Hoth Therapeutics during the 3rd quarter worth approximately $51,000. Institutional investors own 7.08% of the company’s stock.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.